Logo image of BMGL

BASEL MEDICAL GROUP LTD (BMGL) Stock Fundamental Analysis

NASDAQ:BMGL - Nasdaq - VGG0864B1031 - Common Stock - Currency: USD

1.37  +0.19 (+16.1%)

After market: 1.3 -0.07 (-5.11%)

Fundamental Rating

5

BMGL gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 102 industry peers in the Health Care Providers & Services industry. While BMGL has a great health rating, its profitability is only average at the moment. BMGL has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

In the past year BMGL was profitable.
In the past year BMGL had a positive cash flow from operations.
BMGL Yearly Net Income VS EBIT VS OCF VS FCFBMGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 1M 2M 3M 4M

1.2 Ratios

With an excellent Return On Assets value of 12.71%, BMGL belongs to the best of the industry, outperforming 95.10% of the companies in the same industry.
BMGL's Return On Equity of 27.41% is amongst the best of the industry. BMGL outperforms 93.14% of its industry peers.
With an excellent Return On Invested Capital value of 31.78%, BMGL belongs to the best of the industry, outperforming 99.02% of the companies in the same industry.
BMGL had an Average Return On Invested Capital over the past 3 years of 29.84%. This is significantly above the industry average of 9.50%.
The last Return On Invested Capital (31.78%) for BMGL is above the 3 year average (29.84%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 12.71%
ROE 27.41%
ROIC 31.78%
ROA(3y)12.01%
ROA(5y)N/A
ROE(3y)37.76%
ROE(5y)N/A
ROIC(3y)29.84%
ROIC(5y)N/A
BMGL Yearly ROA, ROE, ROICBMGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 10 20 30 40 50

1.3 Margins

With an excellent Profit Margin value of 20.62%, BMGL belongs to the best of the industry, outperforming 99.02% of the companies in the same industry.
With an excellent Operating Margin value of 44.01%, BMGL belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
Industry RankSector Rank
OM 44.01%
PM (TTM) 20.62%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BMGL Yearly Profit, Operating, Gross MarginsBMGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 10 20 30 40

More info and screens

8

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so BMGL is creating value.
The number of shares outstanding for BMGL remains at a similar level compared to 1 year ago.
The debt/assets ratio for BMGL has been reduced compared to a year ago.
BMGL Yearly Shares OutstandingBMGL Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 5M 10M 15M
BMGL Yearly Total Debt VS Total AssetsBMGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 5M 10M 15M

2.2 Solvency

An Altman-Z score of 3.00 indicates that BMGL is not in any danger for bankruptcy at the moment.
BMGL's Altman-Z score of 3.00 is fine compared to the rest of the industry. BMGL outperforms 64.71% of its industry peers.
BMGL has a debt to FCF ratio of 1.71. This is a very positive value and a sign of high solvency as it would only need 1.71 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 1.71, BMGL belongs to the best of the industry, outperforming 82.35% of the companies in the same industry.
A Debt/Equity ratio of 0.56 indicates that BMGL is somewhat dependend on debt financing.
BMGL has a Debt to Equity ratio (0.56) which is in line with its industry peers.
Although BMGL does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF 1.71
Altman-Z 3
ROIC/WACC3.88
WACC8.18%
BMGL Yearly LT Debt VS Equity VS FCFBMGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 2M 4M 6M

2.3 Liquidity

A Current Ratio of 2.26 indicates that BMGL has no problem at all paying its short term obligations.
BMGL has a better Current ratio (2.26) than 78.43% of its industry peers.
BMGL has a Quick Ratio of 2.25. This indicates that BMGL is financially healthy and has no problem in meeting its short term obligations.
BMGL has a Quick ratio of 2.25. This is in the better half of the industry: BMGL outperforms 78.43% of its industry peers.
Industry RankSector Rank
Current Ratio 2.26
Quick Ratio 2.25
BMGL Yearly Current Assets VS Current LiabilitesBMGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 5M 10M 15M

More info and screens

1

3. Growth

3.1 Past

BMGL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.25%, which is quite good.
Looking at the last year, BMGL shows a small growth in Revenue. The Revenue has grown by 3.60% in the last year.
EPS 1Y (TTM)16.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.25%
Revenue 1Y (TTM)3.6%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%3.6%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BMGL Yearly Revenue VS EstimatesBMGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

BMGL is valuated correctly with a Price/Earnings ratio of 15.22.
76.47% of the companies in the same industry are more expensive than BMGL, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 25.82, BMGL is valued a bit cheaper.
Industry RankSector Rank
PE 15.22
Fwd PE N/A
BMGL Price Earnings VS Forward Price EarningsBMGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BMGL indicates a rather cheap valuation: BMGL is cheaper than 86.27% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of BMGL indicates a somewhat cheap valuation: BMGL is cheaper than 79.41% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 13.25
EV/EBITDA 6.59
BMGL Per share dataBMGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.1 0.2 0.3 0.4

4.3 Compensation for Growth

The decent profitability rating of BMGL may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

BMGL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BASEL MEDICAL GROUP LTD

NASDAQ:BMGL (5/23/2025, 9:16:18 PM)

After market: 1.3 -0.07 (-5.11%)

1.37

+0.19 (+16.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap25.74M
AnalystsN/A
Price TargetN/A
Short Float %0.26%
Short Ratio0.09
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 15.22
Fwd PE N/A
P/S 3.3
P/FCF 13.25
P/OCF 13.21
P/B 4.38
P/tB 4.38
EV/EBITDA 6.59
EPS(TTM)0.09
EY6.57%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.1
FCFY7.54%
OCF(TTM)0.1
OCFY7.57%
SpS0.42
BVpS0.31
TBVpS0.31
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 12.71%
ROE 27.41%
ROCE 48.37%
ROIC 31.78%
ROICexc 38.41%
ROICexgc 38.41%
OM 44.01%
PM (TTM) 20.62%
GM N/A
FCFM 24.89%
ROA(3y)12.01%
ROA(5y)N/A
ROE(3y)37.76%
ROE(5y)N/A
ROIC(3y)29.84%
ROIC(5y)N/A
ROICexc(3y)34.59%
ROICexc(5y)N/A
ROICexgc(3y)34.59%
ROICexgc(5y)N/A
ROCE(3y)47.14%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.62
Health
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF 1.71
Debt/EBITDA 0.86
Cap/Depr 1.49%
Cap/Sales 0.08%
Interest Coverage 25.11
Cash Conversion 50.67%
Profit Quality 120.68%
Current Ratio 2.26
Quick Ratio 2.25
Altman-Z 3
F-Score6
WACC8.18%
ROIC/WACC3.88
Cap/Depr(3y)5.99%
Cap/Depr(5y)N/A
Cap/Sales(3y)0.32%
Cap/Sales(5y)N/A
Profit Quality(3y)134.28%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.25%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)3.6%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%3.6%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-3.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.49%
OCF growth 3YN/A
OCF growth 5YN/A